Waters Corporation
WAT
$371.93
-1.65%
Waters Corporation is a leading provider of analytical instruments and associated consumables, specializing in liquid chromatography, mass spectrometry, and thermal analysis tools for the healthcare and life sciences industries. The company is a market leader in high-performance analytical instrumentation, serving pharmaceutical, academic, and industrial laboratories globally. The current investor narrative is heavily focused on the strategic merger completed in early 2026 with BD's life science and diagnostics business, which is expected to transform Waters by adding a significant diagnostics and life science tools segment, driving debates around integration success, growth acceleration, and margin profile evolution.…
WAT
Waters Corporation
$371.93
WAT 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Waters Corporation's 12-month outlook, with a consensus price target around $483.51 and implied upside of +30.0% versus the current price.
Average Target
$483.51
13 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
13
covering this stock
Price Range
$298 - $484
Analyst target range
Analyst coverage is moderate with 13 firms providing estimates, indicating sustained institutional interest. The consensus sentiment appears neutral to cautiously optimistic, as evidenced by recent institutional ratings including 'Hold', 'Equal Weight', and 'Neutral' from major banks, though with a 'Buy' from Guggenheim and an upgrade to 'Outperform' from Wolfe Research in late 2025. The average EPS estimate for the coming period is $21.27, with a tight range from a low of $21.00 to a high of $21.53, signaling strong analyst agreement on near-term earnings prospects, which reduces uncertainty but may also limit surprise potential.
Bulls vs Bears: WAT Investment Factors
The bull case, supported by strong recent momentum, robust profitability, and a compelling forward valuation, currently holds a slight edge over the bear case, which highlights premium trailing multiples and significant integration risks. The most critical tension in the investment debate is the market's expectation embedded in the forward P/E of 23.4x versus the reality of the company's modest pre-merger growth. The resolution of this tension—specifically, whether the merged entity can deliver the accelerated earnings growth necessary to justify and sustain its valuation—will be the primary determinant of stock performance over the next 12-18 months.
Bullish
- Strong Post-Merger Momentum: The stock has surged 31.30% over the past month, decisively breaking a downtrend and signaling a powerful bullish reversal. This momentum is likely fueled by investor optimism regarding the transformative merger with BD's life science and diagnostics business, completed in early 2026.
- Robust Profitability & Cash Flow: Waters maintains exceptional operational efficiency with a Q4 2025 gross margin of 59.79% and an operating margin of 33.31%. The company generates substantial free cash flow (TTM $539.8M), providing a strong financial foundation to fund the merger integration and future growth.
- Solid Financial Health: The balance sheet is strong with a manageable debt-to-equity ratio of 0.58 and a healthy current ratio of 1.73. This low leverage and high liquidity position the company well to navigate the integration phase without financial strain.
- Analyst Consensus on Earnings: Analysts show strong agreement on near-term earnings, with a tight EPS estimate range of $21.00 to $21.53 around an average of $21.27. This consensus reduces uncertainty and provides a clear baseline for post-merger performance expectations.
Bearish
- Premium Trailing Valuation: A trailing P/E of 35.2x is high for a company with modest 6.83% YoY revenue growth in Q4 2025. This premium valuation leaves little room for error and makes the stock vulnerable to multiple compression if growth disappoints post-merger.
- High Execution & Integration Risk: The transformative merger with BD's business introduces significant execution risk. The success of the thesis hinges on seamless integration, synergy realization, and growth acceleration in the new diagnostics segment, which is unproven for Waters.
- Volatile Price Action & High Beta: The stock has a beta of 1.14 and experienced a maximum drawdown of -31.32% in the last year, indicating high volatility and sensitivity to market swings. The recent 31% surge could be an oversold bounce rather than a sustainable trend, increasing near-term risk.
- Modest Organic Growth Trajectory: Pre-merger organic growth is modest, with Q4 2025 revenue up 6.83% YoY. Quarterly revenue has shown lumpiness ($661.7M to $932.4M in 2025), raising questions about the underlying business momentum independent of the merger.
WAT Technical Analysis
The stock is in a volatile recovery phase from a significant drawdown, with a 1-year price change of +7.96% but a 6-month decline of -4.92%. Currently trading at $383.57, it sits at approximately 78% of its 52-week range ($275.05 to $414.15), indicating a recovery from lows but still meaningfully below its peak, suggesting room for further recovery if momentum sustains. Recent short-term momentum is exceptionally strong, with a 1-month surge of +31.30% and a 3-month gain of +20.10%, sharply diverging from the negative 6-month trend and signaling a powerful bullish reversal, potentially driven by post-merger optimism or oversold bounce. Key technical levels are the 52-week high of $414.15 as immediate resistance and the 52-week low of $275.05 as major support; a breakout above resistance would confirm a new uptrend, while a failure could lead to consolidation. With a beta of 1.14, the stock exhibits 14% higher volatility than the broader market, which is relevant for risk-adjusted positioning given its recent price swings.
Beta
1.14
1.14x market volatility
Max Drawdown
-31.3%
Largest decline past year
52-Week Range
$275-$414
Price range past year
Annual Return
+8.2%
Cumulative gain past year
| Period | WAT Return | S&P 500 |
|---|---|---|
| 1m | +21.1% | +5.4% |
| 3m | +16.6% | +10.9% |
| 6m | -6.2% | +11.0% |
| 1y | +8.2% | +28.1% |
| ytd | -2.6% | +11.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
WAT Fundamental Analysis
Revenue growth has been modest but positive, with Q4 2025 revenue of $932.4 million representing a 6.83% year-over-year increase; however, sequential quarterly revenue from Q1 to Q4 2025 shows variability ($661.7M, $771.3M, $799.9M, $932.4M), indicating some quarterly lumpiness but an overall upward trajectory into year-end. The company is solidly profitable, with Q4 2025 net income of $225.2 million and a robust gross margin of 59.79%; the operating margin for the quarter was 33.31%, demonstrating strong operational efficiency and pricing power within its niche. Financial health is sound, evidenced by a manageable debt-to-equity ratio of 0.58, a strong current ratio of 1.73, and substantial free cash flow generation with a TTM figure of $539.8 million, providing ample internal resources to fund growth and the recent merger integration.
Quarterly Revenue
$932362000.0B
2025-12
Revenue YoY Growth
+0.06%
YoY Comparison
Gross Margin
+0.59%
Latest Quarter
Free Cash Flow
$539810000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is WAT Overvalued?
Given a positive net income, the primary valuation metric is the P/E ratio. The trailing P/E is 35.2x, while the forward P/E is notably lower at 23.4x, indicating the market is pricing in significant earnings growth expectations, likely tied to the merged entity's future profitability. Compared to sector averages (data not available in the provided set), a precise premium/discount cannot be quantified; however, a trailing P/E of 35x generally suggests a premium valuation that must be justified by superior growth and margin prospects post-merger. Historically, the stock's own trailing P/E has ranged widely; the current 35.2x is above the 25.1x reported at the end of Q4 2025 but below levels seen in early 2025 (44.3x in Q1), positioning it in the mid-to-upper range of its recent band, reflecting renewed optimism but not extreme historical overvaluation.
PE
35.2x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 22x~50x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
23.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Waters' primary financial risk stems from its premium valuation (35.2x trailing P/E) relative to its recent 6.83% revenue growth, creating a high bar for post-merger performance. While the balance sheet is strong (D/E 0.58), the company faces operational risk in successfully integrating the acquired BD diagnostics business, a new segment with different dynamics. Failure to achieve projected synergies or margin targets could pressure the robust 33.31% operating margin and the substantial $539.8M TTM free cash flow generation.
Market & Competitive Risks: The stock trades at a premium valuation (P/S 7.14, P/CF 34.64) that is vulnerable to compression if growth expectations are not met, especially in a higher interest rate environment that typically pressures growth stock multiples. With a beta of 1.14, WAT is 14% more volatile than the market, amplifying downside during sector rotations or broader market pullbacks. Competitive risks are heightened as the company expands into the diagnostics market, facing established players while managing its core analytical instrumentation business.
Worst-Case Scenario: The worst-case scenario involves a failure to execute the BD merger integration, leading to significant cost overruns, lost customers, and disappointing revenue synergies. This could trigger multiple compression as the forward growth narrative unravels, combined with a broader market downturn. Realistic downside could see the stock re-testing its 52-week low of $275.05, representing a potential loss of approximately -28% from the current price of $383.57, exacerbated by its high beta and recent volatile trading history.
